Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML – OncLive
Posted: February 17, 2021 at 1:50 am
Apamistamab (Iomab-B) conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia (AML), according to interim results from the phase 3 SIERRA trial, which were presented virtually at the 2021 Transplant and Cellular Therapies Meetings.1
In these patients with relapsed or refractory AML, we observed high rates of allogeneic stem cell transplant with curative intent [in] 88% of patients on the Iomab-B arm, 18% of patients who were randomized to the conventional care arm achieved complete remission and received standard of care allo-transplant, and an overall rate of 79% of allo-transplant in all enrolled patients, Boglarka Gyurkocza, MD, said in a virtual presentation.
Investigators sought to prove with this study that targeted radiation to the marrow with apamistamab, a radioactive iodine (131I)labeled anti-CD45 antibody, could enable the successful engraftment of patients despite active disease in the marrow. Safety and robust efficacy had previously been demonstrated with the agent in 271 patients treated in 9 different phase 1 and 2 clinical trials.
The SIERRA trial is looking to enroll 150 patients, and the trial is already over 75% enrolled. Recently, an independent data monitoring committee recommended that the trial continue to the planned full enrollment based on a positive pre-planned ad-hoc analysis.2
In the study, patients with active, relapsed, refractory AML are randomized 1:1 to receive either apamistamab conditioning therapy and allogeneic HCT or conventional care. In the control arm, patients who do not achieve a complete remission (CR) by day 42 are allowed to cross over to receive Iomab-B, and those who do have a CR undergo HCT or receive standard-of-care therapy of the physicians choice.
Durable CR (dCR) rate is the primary end point of the study, characterized as complete response at 6 months after initial CR, and the secondary end point is overall survival (OS) rate at 1 year.
Patients are eligible for enrollment if they have marrow blast count 5% or the presence of peripheral blasts, age 55 years, a Karnofsky score 70, and related/unrelated donor matching at human leukocyte antigen (HLA)-A, HLA-B, HLA-C, and DRB-1. Active, relapsed, or refractory AML was defined for the sake of the trial as primary induction failure after 2 cycles of therapy including chemotherapy or 2 cycles of venetoclax (Venclexta) with a hypomethylating agent or low-dose cytarabine, first early relapse after first CR of less than 6 months, relapse refractory to salvage chemotherapy regimen, or second or subsequent relapse. Secondary or treatment-related AML was also allowed.
In the SIERRA trial, patient-specific dosimetry was used to generate an individualized therapeutic dose to target marrow and spare non-hematopoietic organs. Patients in the investigational arm received a dosimetric dose of apamistamab ( 20 mCi) approximately 19 days prior to HCT followed by a therapeutic dose of apamistamab, which is individually calculated for each patient based on an upper limit of 24 Gy to the liver. After, patients remain on radiation isolation for several days before receiving fludarabine conditioning therapy (30 mg/m2/day for 3 days) and finally low-dose total body irradiation (200 cGy) prior to HCT.
Among the first 75% of enrolled patients (n = 113), patients in the apamistamab arm (n = 56) had a median age of 63 years (range, 55-77), 35% had intermediate risk and 61% had adverse risk, the median
percent of marrow blasts at baseline was 29% (range, 4%-95%), and had received a median of 3 prior treatment regimens (range, 1-7). At randomization, 56% were in primary induction failure, 16% were in first early relapse, 15% had relapsed or refractory disease, and 13% were in their second or later relapse.
In the conventional care arm, the median age was 65 years (range, 55-77), 32% had intermediate risk and 63% had adverse risk, median marrow blasts was 20% (range, 5%-97%), and had received a median of 3 prior regimens (range, 1-6). At randomization, 49% were in primary induction failure, 21% were in first early relapse, 21% had relapsed or refractory disease, and 8.8% were in their second or later relapse. Patients who crossed over to receive apamistamab (n = 30) had similar baseline characteristics.
Forty-nine patients in the apamistamab-randomized arm were able to go on and undergo allogeneic HCT compared with 10 patients in the conventional care arm. In the investigational arm, a median of 646 mCi (range, 3541027) of apamistamab was infused at a dose of 14.7 Gy (range, 4.6-32) to the marrow. The median infused CD34-positive cell count was 5.6 x 106/Kg (range, 1.8-208). Forty-five patients received peripheral blood stem cells (PBSCs), 3 received marrow grafts, 17 had related donors, and 31 had unrelated.
Individualized therapy of Iomab-B provided myeloablative doses of radiation to the marrow, Gyurkocza, a medical oncologist at Memorial Sloan Kettering Cancer Center, commented.
These patients had a median of 30 days (range, 23-60) to HCT after randomization and 14 days (range, 9-22) to neutrophil engraftment, with no graft failure reported. Patients also had 18 days (range, 4-39) until platelet engraftment.
We also observed 100% neutrophil and platelet engraftment in patients who received Iomab-B conditioning, despite a heavy leukemia burden, Gyurkocza said.
In patients in the conventional arm who went on to HCT, conditioning regimens for HCT consisted of fludarabine/melphalan in 2, fludarabine/melphalan/total body irradiation in 1, busulfan/fludarabine in 1, cyclophosphamide/fludarabine/total body irradiation in 2, and 4 had no data on conditioning regimens available. Eight of these patients had PBSCs, 2 had marrow, 3 had related donors, 6 had unrelated, and 1 was unreported.
Median days to HCT was 67 (range, 52-104) with 17 days (range, 13-83) to neutrophil engraftment and 22 days (range, 8-35) to platelet engraftment. There was 1 graft failure.
Among the patients who crossed over to receive apamistamab before HCT, the median infused dose was 592 mCi (range, 313-1013) with 15.5 Gy (range, 6.3-42) to the marrow. The median infused CD34-positive cell count was 5.1 x 106/Kg (range, 1.8-16.1). Twenty-eight patients had PBSCs, 2 had marrow, 10 had related donors, and 20 had unrelated.
Patients had a median of 62 days (range, 36-100) to HCT, 14 days (range, 10-37) to neutrophil engraftment, and 19 days (range, 1-38) to platelet engraftment. No graft failure was reported in this group.
Read the original here:
Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML - OncLive
- Greene, Boebert only lawmakers to vote against bone marrow transplant bill | TheHill - The Hill - April 17th, 2021
- First in the nation, FDA-approved Phase II mesenchymal stem cell therapy for Parkinson's disease begins - Newswise - April 17th, 2021
- Researchers investigate whether stem cell therapy is safe and effective for treatment-resistant bipolar disease - Newswise - April 17th, 2021
- ThermoGenesis : The History of Cell and Gene Therapy - marketscreener.com - April 17th, 2021
- Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today - April 17th, 2021
- Stem cell treatment needed to fight the good fight - Victoria Lookout - April 17th, 2021
- Collaboration Furthers Understanding of Immune Cell Development | Newsroom - UC Merced University News - April 17th, 2021
- Leukemia Cutis: Symptoms and Treatment - Healthline - April 17th, 2021
- More ethnically diverse bone marrow donors needed to save lives - Mail and Guardian - April 17th, 2021
- New pediatric cancer treatment method being used in Iran - Tehran Times - April 17th, 2021
- Adipose-derived Stem Cell OverviewMarket Key Companies, Business Opportunities, Competitive Landscape and Industry Analysis Research Report by 2027 ... - April 17th, 2021
- CRISPR gene therapy for sickle cell disease approved by the FDA - BioNews - April 17th, 2021
- Researchers have created embryos that are part-human and part-monkey - The Economist - April 17th, 2021
- The Recovery Room: News beyond the pandemic April 16 - Medical News Today - April 17th, 2021
- Being bionic: the future of regenerative medicine - Toronto Star - April 17th, 2021
- 'Natural Killer Cells' and Other Promising Cancer Treatments - Barron's - April 17th, 2021
- While ElsaLys continues to work on the filing of marketing approval in Europe and the US for inolimomab, the company confirms the renew of its cohort... - April 17th, 2021
- Mouth Sores from Chemo: Symptoms, Causes, and Treatments - Healthline - February 19th, 2021
- Meet the women hoping to recruit more stem cells donors from Black communities - CTV News - February 19th, 2021
- The Untapped Potential of Cell and Gene Therapy - AJMC.com Managed Markets Network - February 19th, 2021
- Polycythemia vera life expectancy: With treatment and more - Medical News Today - February 19th, 2021
- Novartis and Gates Foundation Team Up To Deliver Affordable Sickle Cell Gene Therapy - BioSpace - February 19th, 2021
- Heartbreak for family of cancer-stricken four-year-old as stem cell donor falls ill at last minute - Press and Journal - February 19th, 2021
- Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the Secret Role of Bone Marrow Derived Stem Cells - DocWire News - February 17th, 2021
- Gergis Explains the Differences Between Acute and Chronic GVHD - Targeted Oncology - February 17th, 2021
- Be The Match encourages people of color to join bone marrow registry - KING5.com - February 17th, 2021
- Types of leukemia: Prevalence, treatment options, and prognosis - Medical News Today - February 17th, 2021
- Cord Blood Banking Services Market projected to expand at a CAGR of 10.9% from 2019 to 2027 KSU | The Sentinel Newspaper - KSU | The Sentinel... - February 17th, 2021
- Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease -... - February 17th, 2021
- Novartis, Gates Foundation pursue a simpler gene therapy for sickle cell - STAT - February 17th, 2021
- Bone marrow transplant shows signs of curing brave little boy with one in a million condition - Shields Gazette - February 17th, 2021
- After 13 years of trials and tribulations RTP firm G1 wins first FDA approval for cancer drug - WRAL Tech Wire - February 17th, 2021
- Global Hematological Cancers Therapeutics Market Is Expected to Reach USD 82.40 billion by 2028 : Fior Markets - GlobeNewswire - February 17th, 2021
- Stem cells efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review - February 4th, 2021
- Understanding bone marrow transplant: The guidelines and the protocols - The New Indian Express - February 4th, 2021
- 'Whatever it takes': Stem cell drive underway to find bone marrow match for girl on Alta. First Nation - CTV Edmonton - February 4th, 2021
- Novel Bone Marrow 'Ingredient' To Help Arthritic Horses The Horse - TheHorse.com - February 4th, 2021
- World Cancer Day 2021: DKMS Announces The Milestone Of Giving 90,000 Blood Cancer Patients Worldwide A Second Chance At Life - PR Newswire India - February 4th, 2021
- Helping others helps Havard through sickness | Community | hannapub.com - The Franklin Sun - February 4th, 2021
- Why Cynata is hopeful its COVID treatment trial will succeed where others have failed - Business News Australia - February 4th, 2021
- Anti-Emetic Drug Effectively Blocks CD93 Signaling in Preclinical Evaluations, Suggesting Suitability in CML - Cancer Therapy Advisor - February 4th, 2021
- World Cancer Day 2021: What are Blood Cancers, Types, Symptoms, Treatment and data in India? - Jagran Josh - February 4th, 2021
- Man who wants to live for 180 years spends Rs 18 lakh to re-inject his own stem cells - Times Now - February 4th, 2021
- India Stem Cell Market speedy growth at US$ 1.27 Bn by 2028 with Thermofisher Scientific India, Pluristem Technologies, Becton Dickinson Private... - February 4th, 2021
- [Full text] Retrospective Study on Implantation of Autologous-Cultured Osteoblasts | ORR - Dove Medical Press - February 4th, 2021
- Orthopedic Regenerative Medicine Market Size to Witness A Lucrative Growth Over 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika... - February 4th, 2021
- World Cancer Day 2021: Know All About The Different Types Of Blood Cancer From Expert - NDTV Doctor - February 4th, 2021
- Bone Marrow Transplantation Market to Surpass US$ 15 Bn By 2027: Acumen Research And Consulting - IT News Online - February 1st, 2021
- Stem Cell Therapy Market 2021: Global Key Players, Trends, Share, Industry Size, Segmentation, Forecast To 2027 KSU | The Sentinel Newspaper - KSU |... - February 1st, 2021
- Covid-19 leads to shortage of bone marrow donors - GO! and Express - February 1st, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - February 1st, 2021
- What Is Leukemia: And How To Prevent It? - Technology Times Pakistan - February 1st, 2021
- A Phase I Study of CYNK-001 Immunotherapy in Adults with Acute Myeloid Leukemia in Remission with Small Amounts Remaining in the Blood - On Cancer -... - February 1st, 2021
- National Institute for Health and Care Excellence (NICE) recommends lenalidomide as a maintenance therapy for people with newly diagnosed multiple mye... - February 1st, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - February 1st, 2021
- Adipose Derived Stem Cell Therapy Market Projected to Witness a Double-Digit CAGR During 2018 to 2026 | Coherent Market Insights - The Courier - January 23rd, 2021
- Stem Cell Therapy Market Size, Growth Opportunities, Trends, Key Players and Forecast to 2027 - The Courier - January 23rd, 2021
- Global Cell Isolation Market SWOT Analysis, Key Indicators, Forecast 2027 : Becton, Dickinson, and Company, Thermo Fisher Scientific KSU | The... - January 23rd, 2021
- 'I was excited to help somebody': Montana Western's Dylan Pope reflects on donating bone marrow - MontanaSports - January 22nd, 2021
- Mesoblast Limited: Is Stemcell Therapy Ready For Prime Time? - Sick Economics - January 22nd, 2021
- [Full text] Identification and Targeting of ThomsenFriedenreich and IL1RAP | OTT - Dove Medical Press - January 22nd, 2021
- BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn Derived Exosome-Based Treatment for COVID-19 ARDS -... - January 22nd, 2021
- [Full text] Effects of Caffeic Acid and Its Derivatives on Bone: A Systematic Revi | DDDT - Dove Medical Press - January 22nd, 2021
- Cancer requires more tutoring, with Meyer continuing to Teaching Cancer a lesson - News - vintontoday.com - January 22nd, 2021
- BrainStorm's Covid-19 ARDS treatment improves lung function in study - Clinical Trials Arena - January 22nd, 2021
- Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy - DocWire News - January 19th, 2021
- Brave Evie Hodgson from Sleights finally has bone marrow transplant after one last 'twist in the tale' - Yorkshire Live - January 19th, 2021
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 19th, 2021
- [Full text] Clinical Analysis of Bloodstream Infections During Agranulocytosis Aft | IDR - Dove Medical Press - January 19th, 2021
- [Full text] Osteonecrosis of the Jaw Beyond Bisphosphonates: Are There Any Unknown | CCIDE - Dove Medical Press - January 19th, 2021
- Shipyard worker Brad Lawson from Walney may have saved a stranger's life with his stem cell donation - NW Evening Mail - January 19th, 2021
- Bone Marrow Processing Systems Market- Global Research Analysis, Trends, Competitive Share and Forecasts 2018 2025 - NeighborWebSJ - January 19th, 2021
- Adipose Derived Stem Cell Therapy Market 2018: Production, Sales, Supply, Demand, Analysis and Forecast To 2026 | BioRestorative Therapies, Inc.,... - January 19th, 2021
- Bone Marrow Processing System Market: Segmental Highlights and Table of Content 2025 - NeighborWebSJ - January 19th, 2021
- Global stem cell banking market Analysis With Key Players, Applications, Trends And Forecasts 2028 - The Courier - January 19th, 2021
- Mum of girl, 8, with rare illness is in 'torture' waiting for results of vital operation - Irish Mirror - January 19th, 2021
- Bone Therapeutics and Rigenerand sign partnership for cell therapy process development - GlobeNewswire - January 19th, 2021
- Unlocking The Unlimited Potential Of Stem Cells - CodeBlue - January 9th, 2021
- Hemostemix steps into the new year with capital and its critical clinical study data in hand - InvestorIntel - January 9th, 2021
- Global Organ and Tissue Transplantation and Alternatives Market to 2024 - Impact Analysis of COVID-19 - Yahoo Finance - January 9th, 2021